Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Obesity levels in the UK may have peaked and could start dropping ‘significantly’ in 2025 due to weight loss jabs, according ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Everything you need to know about using Ozempic, Wegovy, and Mounjaro to shed those extra pounds. We dive into their perks, ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often ...